Health-related quality-of-life assessment in gastrointestinal cancer: Are results relevant for clinical practice?

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 401-406

  Conroy, Thierry ^a,b   Uwer, Lionel ^a   Deblock, Mathilde ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Colorectal cancer; Esophageal cancer; Gastric cancer; Pancreatic cancer; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RALTITREXED; URACIL;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANUS SURGERY; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIET THERAPY; DIGESTIVE SYSTEM CANCER; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; ESOPHAGUS CANCER; GASTRECTOMY; HEPATOBILIARY SYSTEM CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OBSTRUCTIVE JAUNDICE; PANCREAS CANCER; PATIENT INFORMATION; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RECTUM CANCER; REVIEW; STENT; STOMACH CANCER; SURGICAL DRAINAGE; SURVIVAL TIME; TREATMENT PLANNING;

DECISION MAKING; GASTRECTOMY; GASTROINTESTINAL NEOPLASMS; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 34249993099     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32816f7704     Document Type: Review

References (41)

1. Darling G, Eton DT, Sulman J, et al. Validation of the Functional Assessment of Cancer Therapy esophageal cancer subscale. Cancer 2006; 107:854-863. This is a new valid questionnaire to mesure QoL in esophageal cancer patients, to be used with the FACT-G.
2. Blazeby JM, Kavadas V, Vickery CW, et al. A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res 2005; 14:387-393.
3. Viklund P, Lindblad M, Lagergren J. Influence of surgery-related factors on quality of life after esophageal or cardia cancer resection. World J Surg 2005; 29:841-848.
4. Viklund P, Wengström Y, Rouvelas I, et al. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006; 42:1407-1414. This study demonstrates probably for the first time persistence of severe esophageal symptoms after esophageal surgery and also the usefulness of the EORTC specific module, the OES-18.
5. Avery KNL, Metcalfe C, Nicklin J, et al. Satisfaction with care: an independent outcome measure in surgical oncology. Ann Surg Oncol 2006; 13:817-822. Poor QoL after surgery may be compatible with high satisfaction with care, demonstrating that these two patients' outcomes are not correlated.
6. Leibman S, Smithers BM, Gotley DC, et al. Minimally invasive esophagectomy: short- and long-term outcomes. Surg Endosc 2006; 20:428-433. Surprisingly, laparoscopic and thoracoscopic procedures for esophagectomy seriously reduces QoL, apparently not differently from transthoracic surgery according to the results of this series.
7. Blazeby JM, Sanford E, Falk SJ, et al. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2005; 103:1791-1799.
8. Reynolds JV, McLaughlin R, Moore J, et al. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 2006; 93:1084-1090.
9. Bonnetain F, Bouché O, Michel P, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006; 17:827-834. The authors present the first study investigating longitudinal QoL during a randomized study with chemoradiation.
10. Shenfine J, McNamee P, Steen N, et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess 2005; 9:1-121.
11. Van Cutsem E, Dicato M, Arber N, et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol 2006; 17 (Suppl 6):vi13-vi18.
12. Bae JM, Kim S, Kim YW, et al. Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res 2006; 15:1587-1596. This large study in survivors suggests that QoL is similar in patients who underwent total or subtotal gastrectomy.
13. Bonnetain F, Bouché O, Conroy T, et al. Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. Gastroenterol Clin Biol 2005; 29:1113-1124.
14. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991-4997.
15. Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92:547-556.
16. Labori KJ, Hjermstad MJ, Wester T, et al. Symptom profiles and palliative care in advanced pancreatic cancer - a prospective study. Support Care Cancer 2006; 14:1126-1133.
17. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138:618-628; discussion 628-630.
18. Nieveen van Dijkum EJM, Kuhlmann KFD, Terwee CB, et al. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 2005; 92:471-477.
19. Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005; 9:1059-1066; discussion 1066-1067.
20. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228-1236.
21. Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94:785-791.
22. Reni M, Bonetto E, Cordio S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 2006; 6:454-463. This is another demonstration that achievement of an objective tumor response in advanced pancreatic cancer is associated with improved QoL.
23. Artifon ELA, Sakai P, Cunha JEM, et al. Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer. Am J Gastroenterol 2006; 101:2031-2037.
24. Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU(ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92:1650-1654.
25. Blazeby JM, Currie E, Zee BC, et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004; 40:2439-2444.
26. Steel JL, Geller DA, Carr BI. Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. Qual Life Res 2005; 14:1025-1033.
27. Yeo W, Mo FKF, Koh J, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006; 17:1083-1089. This excellent paper demonstates that QoL is an independent prognostic factor for survival in advanced hepatocarcinoma. QoL parameters should be used as stratification factors in clinical trials.
28. Ortholan C, Francois E, Thomas O, et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Colon Rectum 2006; 49:302-310.
29. Park JG, Lee MR, Lim SB, et al. Colonic J-pouch anal anastomosis after ultralow anterior resection with upper sphincter excision for low-lying rectal cancer. World J Gastroenterol 2005; 11:2570-2573.
30. Pocard M, Sideris L, Zenasni F, et al. Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft. Eur J Surg Oncol 2006 Nov 21; [Epub ahead of print]. The authors present similar QoL results for patients with very low rectal cancer undergoing two reconstruction techniques after APR.
31. Guren MG, Eriksen MT, Wiig JN, et al. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol 2005; 31:735-742.
32. Allal AS, Gervaz P, Gertsch P, et al. Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study. Int J Radiat Oncol Biol Phys 2005; 61:1129-1135.
33. Marijnen CAM, van de Velde CJH, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23:1847-1858.
34. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005; 23:1431-1438.
35. Chau I, Norman AR, Cunningham D, et al. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer 2005; 41:1551-1559.
36. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25:424-430. This is a confirmation of the improvement of QoL during fluoropyrimidine adjuvant chemotherapy. It suggests that adverse effects of chemotherapy do not impact strongly on QoL.
37. Efficace F, Bottomley A, Coens C, et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 2006; 42:42-49. This provides confirmation with a multivariate analysis and a bootstrap model that baseline social functioning has prognostic value in metastatic colorectal cancer.
38. Ackland SP, Jones M, Tu D, et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93:1236-1243.
39. Ducreux M, Bouché O, Pignon JP, et al. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology 2006; 70:222-230. This study confirms the detrimental effect of raltitrexed as compared with fluoropyrimidines.
40. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395-1403. This was the first study demonstrating a QoL benefit for hepatic arterial infusion for unresectable hepatic metastases.
41. Arndt V, Merx H, Stegmaier C, et al. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. Eur J Cancer 2006; 42:1848-1857. This was the first longitudinal population-based study on survivors, with an excellent participation rate of 82%.